Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 12 of 12 results for c3

  1. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  2. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

    Evidence summary
    Published
    26 June 2015

  3. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  4. Natural history of varicose veins:- In people with varicose veins at CEAP (Clinical, etiological, anatomical and pathophysiological) stage C2 or C3, what are the factors that influence progression of the disease to CEAP stages C5 or C6?

    CEAP (Clinical, etiological, anatomical and pathophysiological) stage C2 or C3, what are the factors that influence progression of the...

    Research recommendation
    Published
    9 June 2015

  5. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

    Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA778

  6. Optimal interventional and conservative treatments at different stages of disease:- What is the optimal treatment (compression, surgery, endothermal ablation or foam sclerotherapy) for varicose veins at each of the CEAP stages, that is CEAP stages 2–3, CEAP stage 4 and CEAP stages 5–6?

    varicose veins has involved patients with varicose veins in CEAP stages C2 and C3, so little is known of the relative efficacies of...

    Research recommendation
    Published
    9 June 2015

  7. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

    Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.

    Technology appraisal guidance
    Published
    23 October 2024
    View recommendations

    Sections for TA1010

  8. Colorectal cancer (NG151)

    This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).

    NICE guideline
    Last updated
    15 December 2021
    View recommendations

    Sections for NG151

  9. Mobi-C for cervical disc replacement (MIB70)

    NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement

    Medtech innovation briefing
    Published
    28 June 2016

  10. Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

    Evidence-based recommendations on iptacopan (Fabhalta) for treating paroxysmal nocturnal haemoglobinuria in adults.

    Technology appraisal guidance
    Published
    4 September 2024

    Sections for TA1000

  11. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

    NICE guideline
    Published
    15 January 2019
    View recommendations

    Sections for NG119

  12. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used